US Stock MarketDetailed Quotes
IBRX ImmunityBio
- 6.940
- +0.135+1.98%
Close May 22 16:00 ET
- 6.990
- +0.050+0.72%
Post 19:55 ET
4.80BMarket Cap-6425P/E (TTM)
7.180High6.670Low4.14MVolume6.780Open6.805Pre Close28.66MTurnover2.58%Turnover RatioLossP/E (Static)691.57MShares10.53052wk High-6.93P/B1.11BFloat Cap1.25052wk Low--Dividend TTM160.49MShs Float45.420Historical High--Div YieldTTM7.49%Amplitude0.930Historical Low6.929Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
ImmunityBio Stock Forum
ImmunityBio, Inc. (NASDAQ: IBRX) has announced the successful completion and qualification of the drug substance for ANKTIVA® (nogapendekin alfa inbakicept-pmln), paving the way for the production of 170,000 doses. This achievement underscores ImmunityBio's commitment to addressin...
Benzinga· 2 mins ago
ANKTIVA Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA product
ImmunityBio's 400,000 square foot GMP fill-finish facility in Dunkirk, New York on track to be completed in 12-18 months with capacity to produce a million vials annually
Coupled with a recent announcement of BCG availabilit...
No comment yet